Focused Shockwave Therapy for Plantar Fasciopathy
Not yet recruitingNot applicableNCT07471035
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study investigates whether focused Extracorporeal Shockwave Therapy (fESWT) helps people with chronic heel pain, commonly known as plantar fasciitis. Many patients suffer from this condition for more than six months without relief. The study compares two groups: one receiving fESWT treatment plus a specific exercise program, and a "wait-list" group that only performs the exercises at first. The shockwave treatment uses precise sound waves targeted at the painful area to stimulate the body's natural healing process. Researchers will measure if the treatment reduces pain and improves the patient's ability to walk and perform daily activities. Additionally, ultrasound will be used to see if the thickness of the plantar fascia (the tissue under the foot) decreases and returns to a healthier state. The goal is to confirm if fESWT provides a faster and more effective recovery than exercise alone.
Study details
- Official title
- Focused ESWT vs. Wait-list Management for Plantar Fasciopathy: A Randomized Controlled Trial Evaluating Pain, Function, and Ultrasonographic Plantar Fascia Thickness
- Conditions
- Plantar Fascitis
- Chronic Plantar Fasciitis
- Fasciitis
- Interventions
- Device: fESWT
- Other: Wait-list Control: Exercise Only
- Sponsor
- Sierra Varona SL
- Collaborators
- Universidad Europea de Madrid
- Start date
- 2026-04-15
- Primary completion
- 2026-06-30
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male or female aged between 18 and 70 years. Diagnosis of chronic plantar fasciopathy with symptoms persisting for more than 6 months. Presence of plantar fascia (PF) thickness \> 4.0 mm, confirmed by high-resolution ultrasound. Clinical history of localized pain at the medial calcaneal tubercle, specifically upon first steps in the morning or after prolonged rest. Failure of previous conservative treatments (e.g., stretching, orthotics, or medication). Ability to follow the High-Load Strength Training (HLST) exercise protocol. Exclusion Criteria: * Previous treatment with shockwave therapy or corticosteroid injections in the affected foot within the last 6 months. Previous surgery for plantar heel pain. Presence of systemic inflammatory diseases (e.g., rheumatoid arthritis, ankylosing spondylitis). Pregnancy. Coagulopathies or use of anticoagulant medication. Local infection or presence of skin lesions at the application site. Known or suspected malignancy in the treatment area. Presence of neurological conditions or peripheral neuropathy (e.g., tarsal tunnel syndrome).
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07471035